Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEOMETRY-E: capmatinib + osimertinib versus platinum-pemetrexed chemotherapy in MET-amplified EGFR-mutated NSCLC after EGFR-TKI failure
2020-003677-21Phase 3Terminated
- Sponsor
- Novartis
- Start
- Apr 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capmatinib, osimertinib, pemetrexed, cisplatin and carboplatin in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Started Apr 2021; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-003677-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003677-21.